Reviewing preliminary data from the survey (n=1,750!), here are some early observations on a few treatments:
1) Both #pwLC and #pwME benefit remarkably similarly from LDN. Check out the almost identical survey results for overall benefit & number of symptoms improved.
2) People are more likely to benefit from CoQ10 at doses 200 mg or higher, but even then, their overall condition improves only slightly.
2) Both #pwME & #pwLC benefit from anticoagulants (more on this another time - very interesting stuff!).
3) There is a clear increase in benefit when adding on antiplatelets to anticoagulants, but aspirin alone does not help many (78/255).
4) Interestingly, HEPARIN may be more beneficial in both pwME & pwLC than direct oral anticoagulants.
5) The majority of ME/CFS respondents have had ME for over 20 years. 😢
6) The majority of LC respondents have had LC for 6-12 months.
7) NAC dose: Only 29% of those on NAC ≤600 mg daily had sustained benefits (n=195) compared to 51% on NAC >600 mg daily (n=106)
8) Those on primarily EPA supplements reported more benefits than those on mixed fatty acid (DHA+EPA).
9) The majority (~60%) of those who started NK, LK and/or SP did not report any Herxheimer effects or worsening of symptoms at beginning of treatment.
10) The most commonly-used proteolytic enzyme brand = Doctor's Best NK (n=106), with Natto-Serra the 2nd-most used (n=94).
11) 15% (23 in 134), 10% (5/48) and 7.7% (8/104) of those with MCAS reported worsening of MCAS symptoms with NK, LK, & SP, respectively.
12) Proteolytic enzymes (NK, LK, SP) was an uplifting treatment section to review. I need to spend a lot more time analyzing the results but here's some raw data. Nice to see that 11.6-13.6% reported feeling MUCH better on NK, LK, or NK/SP combo.
13) While most people reported benefits from melatonin (n=343), unfortunately the majority reported that only ONE symptom improved (related to sleep).
14) Of the 27 who trialed GUANFACINE, around half reported benefits, with brain fog & sleep improving the most. See raw data.
15) Sadly, very few #pwLC seem to be able to access antivirals. The sample sizes are on the low side but in general the vast majority (~70-80%) who improved on them report that they lost at least some or even all benefits after stopping therapy.
For those who wanted to take the survey a 2nd time for a loved one and/or child but had trouble, here is a link to a fresh link / COPY of the survey. For the 20 #pwME who were kicked out of the survey due to a glitch 2 days ago, please use this link! surveymonkey.com/r/COPYOFTREATME
• • •
Missing some Tweet in this thread? You can try to
force a refresh
TREAT ME covers 150+ medications & supplements. Treatments were selected based on published trials, case reports, other relevant studies, results of earlier surveys I’ve written, direct patient accounts (incl lots of feedback from many of YOU🥰), and my own pharmacist intuition.
The survey has been granted IRB exemption.👍
Furthermore, @OpenMedF will be reviewing a summary of the survey results as they gather info for prospective research studies🤩😍
PLEASE join this effort to investigate #ME & #LongCOVID treatments!
🚨When assessing cardiovascular risk, history of COVID should be considered a risk factor for cardiovascular disease.
Official treatment guidelines should be updated to account for frequent SARS-CoV-2 reinfections & Long COVID.🧵 jamanetwork.com/journals/jama/…
For example:
This atherosclerotic cardiovascular disease (ASCVD) risk calculator estimates the 10-year risk of ASCVD.
One problem: the tool does NOT consider history of COVID & thus likely underestimates risk in this enormous new population.
👇 tools.acc.org/ASCVD-Risk-Est…
The risk calculator is often used to help guide therapy decisions. For example, USPSTF determined that for primary ASCVD prevention, aspirin use has a small net benefit in those aged 40-59 with a ≥10% ten-year risk of ASCVD, but not in those age 60+.
👇 jamanetwork.com/journals/jama/…
Also included:
Treatment & dosing schedule that optimizes efficacy & avoids drug interactions
I also discuss:
Dosing for both adults AND kids
How to optimize absorption w/ low bioavailable supps
When/how to take
Drug interactions when applicable
Brands
How one might combine all 12 of the treatments covered if desired
in vitro vs in vivo concentrations & calculations
etc
Recently I spoke w/ an MD who has treated ~40 #pwLC with an Rx omega-3 fatty acid similar to EPA known as icosapent ethyl (IPE, brand name Vascepa) w/ promising results. Turns out, it may help #pwME too.
Even patients who had suffered from Long COVID for over two years reportedly experienced improvements in sense of taste & smell, fatigue, sleep, joint pain, brain fog, and hair/nail growth. onlinescientificresearch.com/articles/propo…
This MD also treated ~140 acute COVID pts w/ IPE and reportedly none of them developed LC. The MITIGATE trial is currently investigating the ability of Vascepa (IPE) to reduce morbidity & mortality in a cohort of adults with URIs including SARS-CoV-2. ncbi.nlm.nih.gov/pmc/articles/P…
👏Good news for those with MCAS or histamine intolerance:
Serrapeptase (SP) inhibits release of histamine & thus it's plausible that SP may improve MCAS symptoms. Furthermore, co-administration of SP with nattokinase may improve tolerability & efficacy.
Some with MCAS were concerned that lumbrokinase production may involve fermentation. According to the VP of the company that manufactures Boluoke, their product does NOT involve fermentation.
Furthermore, Dr. Kwok confirms that lumbrokinase activity is reduced in acidic (gastric) pH; thus Boluoke includes acid resistant coating. This further supports my hypothesis that these proteolytic enzymes (NK, SP, LK) work better with enteric coatings.